Regeneron Pharmaceuticals entered into development and commercialization agreement with Novartis for developing Regeneron’s IL-1 Trap in phase II clinical trials for treating rheumatoid arthritis. The deal could be worth could be worth up to US$350 M if specific milestones and sales targets are met.